Catalyst

Slingshot members are tracking this event:

Biogen Receives Positive CHMP Opinion for TYSABRI (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BIIB Community voting in process

Additional Information

Additional Relevant Details This positive opinion follows April 2016 EC approvals that granted TYSABRI unlimited validity for the marketing authorization in Europe and updated the European Union product information and physician/patient education materials. The new patient management plan provides an updated risk algorithm which allows physicians to have more individualized benefit-risk discussions with their patients and provides them with clear guidelines to manage their patients appropriately.According to the EMA, the updated risk estimates show that the risk of developing progressive multifocal leukoencephalopathy (PML) is small, and lower than previously estimated, at antibody index values of 0.9 or less, and increases substantially in patients with index values above 1.5 who have been treated with TYSABRI for longer than two years. In patients who tested negative for JC virus antibodies, the PML risk estimate remains unchanged at 0.1 per 1,000 patients. Biogen is committed to patient safety and continues to work closely with the scientific community to provide greater clarity on the minimization of risk for patients taking TYSABRI.
http://media.biogen....
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 31, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Tysabri, Natalizumab, Ositive Chmp Opinion, Multifocal Leukoencephalopathy, Multiple Sclerosis Disease, Disease Modifying Therapy